PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
PTC Therapeutics (PTCT) Tops Q2 EPS by 13c; Offers FY16 Outlook
August 4, 2016 5:10 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.13 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $15.6 million versus the consensus estimate of $14.68 million.
2016 Guidance:
Total ex-U.S. Translarna nmDMD revenues for 2016 are anticipated to... More